Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer

Molecular Diagnosis and Therapy

Volumn 14, Issue 6, 2010, Pages 375-384

  Shiroiwa, Takeru ^a,b   Motoo, Yoshiharu ^c   Tsutani, Kiichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b RITSUMEIKAN UNIVERSITY   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cetuximab, general; Clinical enetics; Colorectal cancer; Cost effectiveness; Diagnostic Tests

Indexed keywords

CETUXIMAB; DIPHENHYDRAMINE;

ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GENE MUTATION; HEALTH CARE COST; HIDDEN MARKOV MODEL; HUMAN; LONG TERM CARE; NATIONAL HEALTH ORGANIZATION; ONCOGENE K RAS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; WILD TYPE;

EID: 79551512524     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/bf03256395     Document Type: Article

References (43)

1. Ministry of Health, Labour and Welfare. Population survey report [in Japanese]. Tokyo: Ministry of Health, Labour and Welfare, 2009
2. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005; 23: 4553-60
3. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-87
4. de Gramont A, Figer A, SeymourM, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47
5. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-37
6. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-12
7. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin formetastatic colorectal cancer: Irinotecan Study Group.NEngl J Med 2000; 343: 905-14
8. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-7
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42
10. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-9
11. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45
12. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-8
13. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-9
14. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit fromcetuximab in advanced colorectal cancer.NEngl JMed 2008; 359: 1757-65
15. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-64
16. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34
17. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet 2010; 375: 1030-47
18. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment.NEngl JMed 2008; 358: 1160-74
19. Messersmith WA, Ahnen DJ. Targeting EGFR in colorectal cancer. N Engl J Med 2008; 359: 1834-6
20. Jiang Y, Kimchi ET, Staveley-O'Carroll KF, et al. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer 2009; 115: 3609-17
21. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-6
22. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine: Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1172-7
23. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1253-8
24. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses: Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1339-41
25. Siegel JE, Torrance GW, Russell LB, et al. Guidelines for pharmacoeconomic studies: recommendations from the Panel on Cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997; 11: 159-68
26. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3: 419-58
27. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38
28. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397-409
29. Mittmann N, Au HJ, Tu D, et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst 2009; 101: 1182-92
30. FeenyD, Furlong W, Boyle M, et al. Multi-attribute health status classification systems: Health Utilities Index. Pharmacoeconomics 1995; 7: 490-502
31. Japanese Society for Cancer of the Colon and Rectum. Clinical guideline for colorectal cancer [in Japanese]. Tokyo: Japanese Society for Cancer of the Colon and Rectum, 2009
32. Social Insurance Research Laboratory. Reimbursement schedule of social insurance and insurance [in Japanese]. Tokyo: Social Insurance Research Laboratory, 2010
33. Jiho, Inc. National health insurance drug price standard [in Japanese]. Tokyo: Jiho, Inc., 2010
34. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York: Oxford University Press, 2006
35. National Institute for Health and Clinical Excellence [NICE]. Guide to the methods of technology appraisal. London: NICE, 2004 [online]. Available from URL: http://www.nice.org.uk/niceMedia/pdf/TAP-Methods.pdf [Accessed 2010 Dec 6]
36. Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-topay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010; 19: 422-37
37. Starling N, Tilden D, White J, et al. Cost-effectiveness analysis of cetuximab/ irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 2007; 96: 206-12
38. National Institute for Health and Clinical Excellence [NICE]. NICE technology appraisal guidance 118: bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. London: NICE, 2007 [online]. Available from URL:http://guidance.nice.org.uk/nicemedia/live/11612/33927/33927.pdf [Accessed 2010 Dec 6]
39. Tappenden P, Jones R, Paisley S, et al. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007; 11: 1-128, iii-iv
40. National Institute for Health and Clinical Excellence [NICE]. NICE technology appraisal guidance 176: cetuximab for the first-line treatment of metastatic colorectal cancer. London: NICE, 2010 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/12216/45198/45198.pdf [Accessed 2010 Dec 6]
41. Claxton K, Briggs A, Buxton MJ, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008; 336: 251-4
42. Zhang Z, Sun J. Interval censoring. Stat Methods Med Res 2010; 19: 53-70
43. Littlejohns P, Garner S, Doyle N, et al. 10 years of NICE: still growing and still controversial. Lancet Oncol 2009; 10: 417-24